intuit strong great busi expens stock
updat forecast estim oct
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
intuit surgic develop produc market robot system
assist minim invas surgeri intuit surgic also provid
instrument dispos accessori warranti servic
system firm place roughli da vinci system hospit
world-wide instal grow number
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research oct
estim oct
price data jan
rate updat jan
currenc amount express
valuat growth profit
methodolog valu compani
decad explos growth becom
victim success tougher comp challeng
key procedur slow trajectori given
moder dvp dvh question surround robot
cost return invest still expect total
number procedur tripl next decad
answer ceil virtual unlimit exist
applic robot surgeri scratch surfac
possibl procedur could migrat robot next
other cardiothorac still offer sizeabl un-
under-penetrated opportun outsid unit
state western europ face similar constraint
face robot surgeri penetr europ
significantli lower includ significantli under-penetrated
market japan robot surgeri still ampl room
grow absenc formid competitor firm
continu domin robot surgeri arena even
cost-consci environ europ adopt
robot surgeri remain robust
believ growth start deceler number
procedur penetr rate hit ceil area
dvp also believ compani increasingli run
manual laparascopi viabl altern need
continu suppli practition tangibl evid benefit
robot surgeri clinic well econom
front focu cost control coupl
rather well-satur field compani increasingli reli
growth intern seen sceptic
past said believ intuit competit posit
remain superb system sale like never reach
growth rate past compani still healthi growth
profil driven mainli expect continu double-digit
growth procedur
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
intuit strong great busi expens
intuit third-quart result follow prior quarter
trajectori make adjust
fair valu estim howev caution
nearli appreci past month
intuit stock trade multipl level seen sinc
earli decad remain impress
compani term growth market posit
believ wide moat virtual impenetr
concern share incorpor growth
expect hard fulfil
procedur growth deceler quarter
respect prior two quarter
still impress growth moder
matur procedur return expect rang flat
low-single-digit growth hernia colorect remain
main sourc strength like remain
next year procedur approach
meaning volum absolut number growth
moder -- incorpor growth forecast
non-u market opportun larger
uptak procedur outsid dvp still quit
roll-out da vinci success far
xi repres vast major new
instal still import note platform
placement still predominantli go facil
total revenu gradual
inch percentag total sale highest share sinc
take comfort placement
go exist user base procedur growth
support demand da vinci
util rate bare move point near-satur
closer impli current growth
improv expect trend
moder compani mix affect lower-
price model sp compani also benefit
scale manufactur process around
platform intuit commit maintain ramped-
oper spend invest made
next-gen platform expect hit market
next year anticip taper
would amiss mention food drug
administr clearanc last week
broad rang colorect gynecolog procedur
total compani process ramp
market develop team five total
announc offici end intuit monopoli
robot surgeri clearanc
europ alreadi hurri reassess take
firm growth prospect moat first
lack clinic data take time
abl conduct large-volum studi support
effect platform second focu
high-volume/lower-valu procedur run
intuit model third trade-off util
senhanc versu da vinci latter four-arm setup
requir anoth scrub surgeon physician
oper room final obviou gap
resourc nine-memb sale team goe
intuit sale market rep
monitor uptak senhanc
global addit indic receiv year
decad away abl challeng intuit
top
valuat growth profit oct
fair valu estim per share
split forecast system sale instrument servic
revenu directli tie procedur volum forecast
top two procedur dvp dvh slow significantli
peak rate penetr rate robot
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
much less attract opinion vast major
instal platform easili absorb addit procedur
util rate go averag sell price
pressur forecast system sale low
singl digit instrument servic revenu expect
grow rapidli midsingl high singl digit
per year line procedur growth forecast
expect margin exceed impli
double-digit growth oper incom period
margin expans trajectori slower
intuit abl deliv recent believ
sever factor slow expans futur
mix toward lower-pr procedur roll-out sp
platform carri lower margin eventu pressur
competit
virtual upsid limit valuat
compani fate tie size procedur market
abl penetr marketplac
hundr million procedur main reason
firm almost alway command lofti valuat
multipl bull case expect firm total
procedur volum grow million would
boost system revenu compound-annual-growth-rate instrument
servic respect overal
revenu growth forecast oper
margin grow minim compani maintain
price structur face competit fair valu
estim jump per share forecast
consid scenario highli unlik
downsid could see downward pressur dvp
acceler dvh lose share laparoscopi
procedur fail make much ground procedur compound-annual-growth-rate
stay around system revenu declin part
owe competit pressur instrument servic
revenu rise midsingl digit margin also
surgeri radic prostatectomi alreadi high
japan dvp growth driven market size
increas thu new market china crucial
deceler overal hysterectomi market like
continu per year on-going pressur
hospit use manual mi possibl coupl
chang percept toward benign hysterectomi
like caus dvh struggl expand
penetr rate beyond current level project
benign dvh volum remain essenti flat
throughout long-term forecast
posit view intuit opportun
gener surgeri colorect hernia procedur
quickli becom second-largest cohort
compani expect gener surgeri market
grow nearli next three year overal
procedur growth rate averag high singl digit
throughout forecast
expect growth rate system revenu becom
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
pressur valuat drop per share
given wide rang outcom believ high
uncertainti rate appropri
expand instal base roughli da
vinci system vast procedur databas think
intuit surgic dug wide moat around busi
system instrument price reflect firm
monopoli statu nich allow
achiev profit rare enjoy medic equip
maker adjust oper margin
fact gross margin intuit system compar
instrument consum compon profit
distinct industri consum
rare attract rapidli grow market
robot surgeri stay impenetr competit
long firm monopoli sooner later
ceas exist sever emerg competitor
none potenti significantli disrupt firm
oper erod return capit intuit
intellectu properti
system grow
instrument base sizeabl barrier
ever-grow clinic databas present biggest
challeng new entrant amass bodi data
intuit possess new competitor still
year away european approv
convinc enough hospit purchas trial
instrument extens period train robot-na
da vinci-train surgeon recruit will patient
howev certain compet instrument --
price attract -- may make inroad procedures/speci
current under-penetrated intuit particularli
hospit balk da vinci cost
cost becom exorbit averag system price
around million repres larg portion typic
would need compel technolog price differ
switch machin wear natur
upgrad cycl around five eight year given need
purchas new instrument procedur instal
system provid rel depend stream
revenu per procedur long surgeon continu use
biggest threat intuit moat futur robot
surgeri gener plausibl cash-strap
hospit receiv addit reimburs robot
usag may opt plod yet cheaper altern
manual laparoscopi particularli clinic bodi work
support robot surgeri tradit mi lack
also plausibl robot surgeri may face applic
limit consid number variou
procedur alreadi perform da vinci seem
moat trend stabl stage game intuit
surgic meaning direct competitor
extend definit competit includ manual
laparoscopi intuit abil expand competit
unchalleng robot surgeri field
increasingli run manual surgeri particularli
ventur outsid core surgic area even
struggl take share manual lap
convert open procedur robot lack
evid clinic benefit particularli benign surgeri
instead reli cosmesi eas use sell dvh
increasingli tougher sell
becom
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
cash-strap hospit particularli addit
reimburs lack switch cost anoth
robot high hospit custom term money
train surgeon switch manual lap done
significantli less effort given surgeon familiar
mi forecast procedur overal
convert robot surgeri next decad around
procedur compound-annual-growth-rate firm profit per
procedur come sever reason
fewer greenfield opportun marketplac fulli
satur lower averag sell price dispos
compet manual lap platform share
special challeng procedur sell cycl
intuit research develop product
also declin fewer procedur opportun
emerg innov cycl low-hang fruit
pick compani invest heavili
order penetr variou surgic special
outsid core urology/gynaecolog market final
see nois competit front
threat firm moat might make certain procedur
suscept price pressur
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oth da vinci system assist multipl type
hospit drive procedur
intuit surgic potenti specialis rival
on-going high-margin instrument sale servic
revenu provid clinic case histori
sought surgeon hospit administr
ointuit surgic direct rival grow
base user build career
profici da vinci
owe may see emerg
competit particularli lower-cost procedur
oth firm averag utilis rate well
maximum particularli outsid unit state
instal challeng hospit tri
maxim exist da vinci util
orobot gynaecolog slow like
continu declin forese futur along
hysterectomi gener owe gener
overusag procedur
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
intuit balanc sheet spotless zero debt
ampl cash compani could arguabl leverag
balanc sheet strict cash deploy polici limit
usag tuck-in acquisit reinvest share
buyback compani resum buy-back polici recent
could acceler need balanc sheet
health concern extrem limit
one key long-term risk
competitor introduc compel altern da vinci
procedur siphon intuit growth
opportun potenti reduc profit
busi also concern recent emerg regard
surgic train profici hospit low
procedur volum well number incid use
da vinci robot result current pend
food drug administr probe
explicitli project liabil neg outcom trend
system could damag firm reput
caus hospit question purchas new
system use instal system litig may
also result financi hit although explicitli
forecast model final robot surgeri yet
establish good altern manual laparoscopi
certain procedur benign hysterectomi well
gener surgeri reimburs distinguish
manual
instrument cost hospit forc eat
differ two procedur clinic
benefit well establish manual laparoscopi may
prevail seen evid slow
penetr rate benign dvh declin growth
robot mi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
intuit surgic remark record come
organ growth return capit technolog
revolutionari testament intuit
vision manag team abil drive
adopt expand area
superb monopolist posit technolog vision
key rational behind previou exemplari
stewardship rate howev decid
standard rate appropri see
chink intuit armour could trace
campaign drive robot system instal result
satur marketplac unit state
emphasi large-volum procedur compani steer
away root nich area ripe robot
surgeri instead invit scrutini clinic
econom benefit patient hospit fda probe
litig sever develop past
year make exemplari rate award
best manag team coverag tougher
justifi said applaud compani dedic
 shield robust return capit avers
unrel area via acquisit
repres date owner name posit common share held report holder issuer
fidel manag research compani
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
yet anoth robust quarter intuit rais fve
intuit second-quart result surpris us
particularli procedur growth side follow
procedur growth first quarter intuit deliv
growth second quarter enabl rais
procedur guidanc second time year
slightli upgrad total procedur growth year
correspond increas instrument servic
revenu underestim firm growth
trajectori rais fair valu estim
per share per share even
intact
still buy sustain year-
to-dat global procedur growth conced
growth
far significantli exceed
expect firm continu see robust uptak
robot gener surgeri surprisingli resili growth
matur applic uptick applic
servic revenu roll-out model
far success
adjust gross margin continu improv year year
expect trend moder
compani mix affect lower-pr model
sp compani also benefit scale
manufactur process around platform intuit
continu ramp oper spend
invest made next-gen platform expect hit
market next year anticip taper
go even long-term year
earn organ growth current valuat
impli time ep forecast lofti
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
